Target intelligence / Profile preview

Serine/threonine-protein kinase ULK1 (ULK1) (ULK1)

Target
ULK1
Molecular classification
Enzyme (UniProt, P42768), Serine/threonine-protein kinase (UniProt, P42768)
01

Overview

UNC-51-like autophagy-activating kinase 1 (ULK1) is a critical serine/threonine kinase that serves as the primary initiator of the macroautophagy pathway in mammalian cells (UniProt, P42768). It functions as the catalytic subunit of the ULK complex, which integrates signals from metabolic sensors like mTORC1 and AMPK to trigger autophagosome formation (PubMed, 29233870). In the context of oncology, ULK1 is often upregulated to promote tumor cell survival under nutrient-deprived conditions and to facilitate resistance against chemotherapy and targeted therapies (PubMed, 30554882). Conversely, its dysregulation is linked to the pathogenesis of neurodegenerative diseases, where inadequate autophagy leads to the toxic accumulation of misfolded proteins (PubMed, 31160674). Pharmacological modulation of ULK1 is an active area of research, with inhibitors like DCC-3116 currently in clinical trials to enhance the efficacy of MAPK pathway inhibitors in RAS-mutated cancers (, NCT04892501). Additionally, small-molecule activators are being explored for their potential to restore autophagic flux in proteinopathies and metabolic disorders (PubMed, 28846096).

Other names
UNC-51-like autophagy-activating kinase 1 (UniProt, P42768)Autophagy-related protein 1 homolog (UniProt, P42768)ATG1 (UniProt, P42768)hATG1 (UniProt, P42768)UNC51 (UniProt, P42768)
02

Mechanism of action

Small-molecule inhibition of the ULK1 kinase domain to block autophagosome initiation and sensitize cells to metabolic stress (PubMed, 25915708).

03

Biological functions

Autophagy initiation (PubMed, 29233870)Mitophagy (PubMed, 29233870)Nutrient sensing (PubMed, 29233870)Signal transduction (PubMed, 29233870)Cell survival (PubMed, 29233870)
04

Disease associations

Cancer (PubMed, 30554882)Neurodegenerative disease (PubMed, 31160674)Inflammation (PubMed, 30554882)Metabolic disorder (PubMed, 30554882)
05

Safety considerations

Impairment of basal autophagy (PubMed, 30224753)Potential neurotoxicity (PubMed, 30224753)Hepatotoxicity (PubMed, 30224753)Accumulation of damaged organelles (PubMed, 29233870)
06

Interacting drugs

DCC-3116 (ClinicalTrials.gov, NCT04892501)

4 more in the full profile.

07

Biomarkers

Phospho-ULK1 at Ser757 (PubMed, 21258367)Phospho-ULK1 at Ser555 (PubMed, 21258367)p62/SQSTM1 accumulation (PubMed, 26795239)LC3-II/LC3-I ratio (PubMed, 26795239)

Source types: Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Serine/threonine-protein kinase ULK1 (ULK1) (ULK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serine/threonine-protein kinase ULK1 (ULK1) (ULK1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call